StreetAlpha.app
Home › Stocks › PCRX

Pacira BioSciences, Inc. (PCRX)

Healthcare
$36.48
▲ +0.05%
LAST CLOSE · NOV 16

Pacira BioSciences sells pain treatments such as EXPAREL and ZILRETTA to patients and healthcare providers. It last closed at $36.48 on Nov 16, up 0.05% on the day. The next earnings report for PCRX is expected around Thu, Feb 4, 2027, after the close. For the quarter ended Sep 2026, PCRX reported EPS of $0.70 on revenue of $176.7M, with revenue down 1.6% from a year ago. Over its last 8 reports the stock moved an average of 4.7% the session after earnings. Over the last 12 months PCRX insiders bought $0 of stock on the open market and sold $2.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is PCRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PCRX.

Key Stats

Last 12 months
Results
Revenue
$743.3M
+3.7% vs a year ago
Net income
$37.7M
+76.0% vs a year ago
EPS (diluted)
$0.93
+97.9% vs a year ago
Free cash flow
$169.0M
22.7% margin
Valuation
Market cap
$1.5B
40.1M shares
P/E
39.2
Price over 12 month EPS
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$247.0M
At Sep 30
Debt
$293.6M
At Sep 30
Shareholder equity
$712.3M
Buybacks
$98.3M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $541.5M$541.5MFY2021FY2022: $666.8M$666.8MFY2022FY2023: $675.0M$675.0MFY2023FY2024: $701.0M$701.0MFY2024FY2025: $726.4M$726.4MFY2025

From PCRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 4
Estimated date · After the close
Reported EPS
$0.70
Quarter ended Sep 2026
Year ago EPS
$0.12
+483.3% on a GAAP basis
Revenue
$176.7M
−1.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.35Dec '24Mar 2025: $0.10Mar '25Jun 2025: -$0.11Jun '25Sep 2025: $0.12Sep '25Dec 2025: $0.04Dec '25Mar 2026: $0.07Mar '26Jun 2026: $0.12Jun '26Sep 2026: $0.70Sep '26Latest $0.70
Revenue by quarter
Dec 2024: $187.3MDec '24Mar 2025: $168.9MMar '25Jun 2025: $181.1MJun '25Sep 2025: $179.5MSep '25Dec 2025: $196.9MDec '25Mar 2026: $177.4MMar '26Jun 2026: $192.4MJun '26Sep 2026: $176.7MSep '26Latest $176.7M
How PCRX moved after its last 8 reports
Average move the session after a report ±4.7%
Aug 4, 2026After the close−10.0%
Apr 30, 2026After the close−4.1%
Feb 26, 2026After the close−3.0%
Jan 8, 2026After the close−9.6%
Nov 6, 2025After the close+4.5%
Aug 5, 2025After the close−0.6%
May 8, 2025After the close+0.8%
Feb 27, 2025After the close−5.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PCRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PCRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PCRX

Technical Analysis

PCRX · as of the Nov 16 close · updated each morning
Uptrend, overbought

The stock is 0% above its 20 day and 14% above its 50 day average. It is 29% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 83), overbought. The nearest support is the 20 day average at $36.41, and the nearest resistance the Pivot R1 at $36.49.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityLow, 0.7%/day
Key levels
$36.6652 week high+0.5%
$36.50Swing high (Nov 10)+0.1%
$36.49Pivot R1+0.0%
$36.48Pivot+0.0%
$36.48Pivot S1+0.0%
$36.48Last close
$36.4120 day average−0.2%
$36.38Swing low (Nov 4)−0.3%
$31.3950 day average−14.0%
$28.41100 day average−22.1%
$25.73200 day average−29.5%
$18.8052 week low−48.5%
Indicators
RSI (14)82.85Overbought above 70Overbought
MACD1.23Below its signal lineBearish
Stochastic77.8Middle of its rangeNeutral
ADX (14)69.7Strong uptrend
Williams %R-13.3Oversold below −80, overbought above −20Overbought
CCI (20)127.5Oversold below −100, overbought above 100Overbought
Rate of change+0.2%Change over 10 sessionsBullish
ATR (14)$0.26Typical daily range, 0.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for PCRX

What happened before

See how PCRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PCRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PCRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2011.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PCRXHow many large options trades hit PCRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

PCRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●126 buying vs 110 selling
  • ▲Held by funds +14.0 pts
  • ▲Funds holding +5
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding261256+2.0%
In funds' top 1032+50.0%
Held by funds146.3%132.3%+14.0 pts
New / increased30 / 9636 / 81+7.7%
Reduced / sold out85 / 2584 / 260.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PCRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PCRX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.4M12 sales · 5 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $627K2026-01 sold $34K2026-02 sold $353K2026-03 sold $85K2026-04 sold $628K2026-06 sold $372K2026-08 sold $71K2026-10 sold $218KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 8Lauren RikerSenior Vice President, FinanceSale plan6,000$36.32$218K
Aug 17Jonathan SloninChief Medical OfficerSale plan3,040$23.23$71K
Jun 11Lauren RikerSenior Vice President, FinanceSale plan6,115$23.50$144K
Jun 4Kristen WilliamsChief Administrative OfficerSale plan10,259$22.27$228K
Apr 23Shawn CrossCFOSale plan12,941$25.16$326K
Apr 22Shawn CrossCFOSale plan12,059$25.09$303K
Every insider buy and sale for PCRX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PCRX insider trades →

From SEC Form 4 filings by PCRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PCRX is in one of them and how their past PCRX trades turned out.

PCRX in the AI portfolios
Loading…

PCRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PCRX in an article yet. Here's the latest on the wider market.

PCRX in the news

PCRX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 26
Who traded PCRX · since 2019
Latest 5 filings of 10
$1K – $15KTraded Jan 25, 2021Filed Aug 26, 2021
$1K – $15KTraded May 6, 2021Filed Jun 23, 2021
$1K – $15KTraded Apr 20, 2021Filed Jun 12, 2021
$1K – $15KTraded Jan 15, 2021Filed Mar 5, 2021
$1K – $15KTraded Nov 2, 2020Filed Mar 5, 2021
PersonTypeAmountTradedFiledDelay
Tom MalinowskiD · NJBuy$1K – $15KJan 25, 2021Aug 26, 2021213 d
Tom MalinowskiD · NJBuy$1K – $15KMay 6, 2021Jun 23, 202148 d
Tom MalinowskiD · NJBuy$1K – $15KApr 20, 2021Jun 12, 202153 d
Tom MalinowskiD · NJBuy$1K – $15KJan 15, 2021Mar 5, 202149 d
Tom MalinowskiD · NJBuy$1K – $15KNov 2, 2020Mar 5, 2021123 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Pacira BioSciences

Pacira BioSciences is a pharmaceutical company based in Brisbane, California. It sells pain treatments that do not rely on opioids. Its main products are EXPAREL, a local pain treatment used around surgery that works over an extended period, ZILRETTA, a knee injection that releases medicine over time for osteoarthritis pain, and the iovera handheld device, which uses cold to block pain signals in targeted nerves. Its customers include patients and the healthcare providers who treat them.

Headquarters
Brisbane, CA